Rapport Therapeutics, Inc.
RAPPNasdaqCIK 2012593HealthcareFiscal year ends Dec 31
Reports and events: 38 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-3017:12 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-441851 |
| 2026-10-2006:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-425647 |
| 2026-08-0507:30 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-333862 |
| 2026-08-0507:17 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-333853 |
| 2026-06-1016:12 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-265841 |
| 2026-05-0707:30 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-210355 |
| 2026-05-0707:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-210324 |
| 2026-04-2307:20 ET | DEF 14A | Proxy statementPeriod 2026-06-10 | 0001193125-26-171828 |
| 2026-04-2116:50 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events | 0001193125-26-167078 |
| 2026-03-1007:25 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-099360 |
| 2026-03-1007:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-099336 |
| 2026-01-0708:35 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-005499 |
| 2026-01-0707:30 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-005446 |
| 2025-11-0607:30 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-268096 |
| 2025-11-0607:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-268072 |
| 2025-09-1817:32 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-25-091350 |
| 2025-09-1017:22 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-25-200205 |
| 2025-09-0816:02 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-198322 |
| 2025-09-0806:12 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-197610 |
| 2025-08-0707:30 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-104565 |
| 2025-08-0707:15 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-104557 |
| 2025-06-1816:30 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-087921 |
| 2025-06-0216:07 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-080247 |
| 2025-05-0807:30 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-066393 |
| 2025-05-0807:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-066376 |
| 2025-04-2406:07 ET | DEF 14A | Proxy statementPeriod 2025-06-17 | 0001193125-25-092133 |
| 2025-03-1107:30 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-036828 |
| 2025-03-1107:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-036822 |
| 2025-03-0307:14 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-043405 |
| 2025-01-1006:30 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-004045 |
| 2024-11-0707:30 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-122801 |
| 2024-11-0707:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-122792 |
| 2024-08-0807:40 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-093334 |
| 2024-08-0807:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093321 |
| 2024-06-1415:59 ET | SC 13D | Ownership report, active investor | 0001104659-24-071732 |
| 2024-06-1016:09 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-24-158327 |
| 2024-06-0306:08 ET | S-1/A | Registration statement, amended | 0001193125-24-152294 |
| 2024-05-1716:02 ET | S-1 | Registration statement | 0001193125-24-141704 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 19:33 ET. Listed shows no prices and gives no investment advice.